TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Cantor Fitzgerald Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $152
Cantor Fitzgerald Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Analyst Ratings
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics Analyst Ratings
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)
RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
Sarepta Therapeutics Analyst Ratings
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
Evercore ISI Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Buy Rating Affirmed for Sarepta Therapeutics Amid Positive Revenue Outlook and Strong Pipeline Potential
Sarepta Therapeutics Price Target Cut to $181.00/Share From $182.00 by RBC Capital
Citigroup Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $160
Evercore Upgrades Sarepta to Outperform, but Lowers Price Target